Given the substantial number of events found during follow-up among patients with ATTR-CM without HF symptoms in our study and the underlying pathophysiological mechanism of the disease, early modification of its natural history by specific TTR therapies could be meaningful. The gene discussed is TTR; the disease is hydrops fetalis.